In our laboratory, we have demonstrated that TLM could enhance the anti-cancer effects of sorafenib and CFM 4.16 in the rociletinib-resistant H1975 NSCLC xenograft model, lowering the protein expression of p-EGFR/EGFR, Nanog, Sox2, Oct4, pMET/MET, TGF-beta, and MMP9 while raising the expression of E-cadherin protein [34]. The gene discussed is SOX2; the disease is cancer.